

May 25, 2021

British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission

Dear Sir/Madam:

Re: BetterLife Pharma Inc. (the “Company”)

We refer to the prospectus supplement of BetterLife Pharma Inc. (the “Company”) dated May 25, 2021 relating to the issuance of units comprising common shares and common share purchase warrants with a total offering price of such securities of \$5,500,000 million.

We consent to being named and to the use, through incorporation by reference in the above-mentioned prospectus supplement, of our report dated June 1, 2020, to the Board of Directors and Shareholders of the Company on the following financial statements:

- a. Consolidated statements of financial position as at January 31, 2020 and January 31, 2019; and,
- b. Consolidated statements of comprehensive loss, consolidated statements of shareholders’ equity and consolidated statements of cash flows and the notes to the consolidated financial statements for each of the years in the two year period ended January 31, 2020 and January 31, 2019.

We report that we have read the prospectus supplement and all information specifically incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor’s consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Sincerely,

¹

MNP SENCRL, srl

encls.

¹ CPA auditor, CA, public accountancy permit No. A122514